An Exploratory Phase II Study to Determine the Safety, Tolerability, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults with DSM-5 Intermittent Explosive Disorder (IED)

Administered By

Awarded By

Contributors

Start/End

  • November 3, 2014 - September 22, 2015